These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39279643)

  • 41. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human Enteroid Monolayers: A Novel, Functionally-Stable Model for Investigating Oral Drug Disposition.
    Arian C; O'Mahony E; MacDonald JW; Bammler TK; Donowitz M; Kelly EJ; Thummel KE
    Drug Metab Dispos; 2024 Aug; ():. PubMed ID: 38744527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters.
    Mooij MG; Schwarz UI; de Koning BA; Leeder JS; Gaedigk R; Samsom JN; Spaans E; van Goudoever JB; Tibboel D; Kim RB; de Wildt SN
    Drug Metab Dispos; 2014 Aug; 42(8):1268-74. PubMed ID: 24829289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-Culture System of Human Enteroids/Colonoids with Innate Immune Cells.
    Staab JF; Lemme-Dumit JM; Latanich R; Pasetti MF; Zachos NC
    Curr Protoc Immunol; 2020 Dec; 131(1):e113. PubMed ID: 33166041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).
    Haslam IS; Wright JA; O'Reilly DA; Sherlock DJ; Coleman T; Simmons NL
    Drug Metab Dispos; 2011 Dec; 39(12):2321-8. PubMed ID: 21930826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in Expression and Function of Placental and Intestinal P-gp and BCRP Transporters during Pregnancy.
    Szatmári P; Ducza E
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.
    Harati R; Villégier AS; Banks WA; Mabondzo A
    J Neuroinflammation; 2012 Dec; 9():273. PubMed ID: 23253775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of equine enteroids and enteroid-derived 2D monolayers that are responsive to microbial mimics.
    Hellman S
    Vet Res; 2021 Aug; 52(1):108. PubMed ID: 34391473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
    Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
    Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
    Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
    Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Type 1 diabetes human enteroid studies reveal major changes in the intestinal epithelial compartment.
    Bharadiya V; Rong Y; Zhang Z; Lin R; Guerrerio AL; Tse CM; Donowitz M; Singh V
    Sci Rep; 2024 May; 14(1):11911. PubMed ID: 38789719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.
    Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
    Pharmacol Res Perspect; 2020 Feb; 8(1):e00544. PubMed ID: 31988753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishing Human Intestinal Enteroid/Organoid Lines from Preterm Infant and Adult Tissue.
    Stewart CJ; Estes MK; Ramani S
    Methods Mol Biol; 2020; 2121():185-198. PubMed ID: 32147796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
    Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
    Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.